(Q34150008)

31 July 2017

title

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations (English)

1 reference

31 July 2017

1 reference

ChEBI release 2020-05-28

1 reference

6

A Tefferi

1 reference

31 July 2017

3

F. Passamonti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21079613

27 August 2024

author name string

A. Pardanani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21079613

27 August 2024

A. M. Vannucchi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21079613

27 August 2024

F. Cervantes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21079613

27 August 2024

T. Barbui

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21079613

27 August 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21079613

27 August 2024

publication date

16 November 2010

1 reference

full work available at URL

31 July 2017

https://www.nature.com/articles/leu2010269.pdf

1 reference

https://api.crossref.org/works/10.1038/LEU.2010.269

https://www.nature.com/articles/leu2010269

27 August 2024

1 reference

https://api.crossref.org/works/10.1038/LEU.2010.269

27 August 2024

1 reference

31 July 2017

volume

25

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

218-225

1 reference

Translation of the Philadelphia chromosome into therapy for CML.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Mutation in TET2 in myeloid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Mutations of ASXL1 gene in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Taxing sugar-sweetened beverages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

New and old treatment modalities in primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

7 January 2021

Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

7 January 2021

Myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

7 January 2021

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

7 January 2021

Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

7 January 2021

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

7 January 2021

Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

7 January 2021

Repeated and preemptive palliative radiotherapy of symptomatic hepatomegaly in a patient with advanced myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

7 January 2021

Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

7 January 2021

A phase-2 trial of low-dose pomalidomide in myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

7 January 2021

Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.269

7 January 2021

Hydroxyurea Effect On Marked Splenomegaly Associated with Primary Myelofibrosis: Response Rates and Correlation with JAK2V617F Allele Burden.

https://api.crossref.org/works/10.1038/LEU.2010.269

35

1 reference

Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2V617F Allele Burden

27 August 2024

https://api.crossref.org/works/10.1038/LEU.2010.269

42

1 reference

A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms

27 August 2024

https://api.crossref.org/works/10.1038/LEU.2010.269

45

1 reference

Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.

27 August 2024

https://api.crossref.org/works/10.1038/LEU.2010.269

55

1 reference

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

27 August 2024

https://api.crossref.org/works/10.1038/LEU.2010.269

57

1 reference

Generation of Functional Lymphoid (Natural Killer) Cells From Human ESC-Derived Hemangioblasts.

27 August 2024

https://api.crossref.org/works/10.1038/LEU.2010.269

63

1 reference

27 August 2024

Identifiers

DOI

10.1038/LEU.2010.269

1 reference

Dimensions Publication ID

31 July 2017

1000067692

0 references

1 reference